Clinical bottom line
Sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as effective therapies for heart failure (HF) management beyond their original indication for type 2 diabetes mellitus. Evidence supports their use in reducing HF hospitalization and cardiovascular mortality across a broad spectrum of patients, including those without diabetes. These agents improve cardiac and renal outcomes by mechanisms independent of glycemic control, marking a paradigm shift in HF treatment. However, patient selection and long-term safety require ongoing evaluation (Grigoriou et al., 2025; Bhandari et al., 2024).
What the evidence shows
Grigoriou et al. (2025) review the role of SGLT2 inhibitors in cardio-renal-metabolic syndrome, highlighting their multifaceted benefits in HF patients regardless of diabetic status. They emphasize improvements in ventricular loading conditions, natriuresis, and metabolic efficiency as key mechanisms.
Bhandari et al. (2024) provide a comprehensive overview of SGLT2 inhibitors’ clinical impact in HF, noting consistent reductions in hospitalization rates and mortality in both heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF). They discuss landmark trials such as DAPA-HF and EMPEROR-Preserved that underpin current guideline recommendations.
Fatima et al. (2023) explore cardiovascular benefits beyond glucose lowering, including anti-inflammatory and antifibrotic effects, which may contribute to improved myocardial remodeling and function.
Joher et al. (2025) present a systematic review and meta-analysis confirming that SGLT2 inhibitors significantly reduce HF hospitalization risk in type 2 diabetes, with emerging data supporting extension to non-diabetic HF populations.
Nandave et al. (2024) discuss unmet needs and therapeutic potential, advocating for broader adoption of SGLT2 inhibitors in congestive heart failure management, while recognizing gaps in understanding optimal timing and combination with other HF therapies.
Caveats and uncertainty
Most evidence derives from randomized controlled trials with selected populations; real-world effectiveness and safety require further study.
Long-term effects on renal function and electrolyte balance need continued monitoring.
Optimal patient selection criteria, particularly in HFpEF and advanced renal impairment, remain areas of active research.
Potential adverse effects such as genital infections, volume depletion, and ketoacidosis warrant vigilance.
Cost and access may limit widespread implementation in some settings.
How this may change practice
Clinicians should consider SGLT2 inhibitors as foundational therapy in HF patients irrespective of diabetes status, integrating them early alongside established treatments.
Routine assessment of renal function and volume status is essential to optimize safety.
Patient education on potential side effects and adherence is critical.
Multidisciplinary collaboration can facilitate comprehensive cardio-renal-metabolic care.
Ongoing guideline updates will likely expand indications and refine treatment algorithms.
Participation in registries and pragmatic trials will enhance understanding of long-term outcomes.